Technical Analysis for CGON - CG Oncology, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Down 5% | about 2 hours ago |
| Fell Below Lower Bollinger Band | about 2 hours ago |
| Fell Below Previous Day's Low | about 2 hours ago |
| Possible NR7 | about 4 hours ago |
| Possible Inside Day | about 4 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Virotherapy Immunotherapies Oncolytic Virus
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Virotherapy Immunotherapies Oncolytic Virus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 50.23 |
| 52 Week Low | 28.55 |
| Average Volume | 621,410 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 38.65 |
| 20-Day Moving Average | 36.77 |
| 10-Day Moving Average | 37.24 |
| Average True Range | 3.63 |
| RSI (14) | 32.43 |
| ADX | 20.72 |
| +DI | 13.68 |
| -DI | 29.61 |
| Chandelier Exit (Long, 3 ATRs) | 36.09 |
| Chandelier Exit (Short, 3 ATRs) | 40.92 |
| Upper Bollinger Bands | 43.03 |
| Lower Bollinger Band | 30.52 |
| Percent B (%b) | -0.04 |
| BandWidth | 34.02 |
| MACD Line | -1.44 |
| MACD Signal Line | -0.69 |
| MACD Histogram | -0.7512 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 34.97 | ||||
| Resistance 3 (R3) | 35.52 | 34.42 | 34.15 | ||
| Resistance 2 (R2) | 34.42 | 33.16 | 34.15 | 33.87 | |
| Resistance 1 (R1) | 32.22 | 32.38 | 31.67 | 31.67 | 33.59 |
| Pivot Point | 31.12 | 31.12 | 30.85 | 30.85 | 31.12 |
| Support 1 (S1) | 28.92 | 29.86 | 28.37 | 28.37 | 26.45 |
| Support 2 (S2) | 27.82 | 29.08 | 27.55 | 26.17 | |
| Support 3 (S3) | 25.62 | 27.82 | 25.90 | ||
| Support 4 (S4) | 25.07 |
